Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
49
MKKGY Quote, Financials, Valuation and Earnings
Last price:
$27.80
Seasonality move
:
-0.62%
Day range:
$27.64 - $28.01
52-week range:
$24.32 - $31.80
Dividend yield:
1.8%
P/E ratio:
18.43x
P/S ratio:
2.57x
P/B ratio:
5.98x
Volume:
62.7K
Avg. volume:
158.4K
1-year change:
-5.83%
Market cap:
$60.4B
Revenue:
$22.9B
EPS (TTM):
$1.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MKKGY
Merck KGaA
|
$6B | $0.54 | 5.76% | 47.26% | $34.04 |
|
BAYRY
Bayer AG
|
$11.2B | $0.13 | 2.56% | 25.01% | $10.87 |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.85% | -86.85% | $137.68 |
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -14.98% | $12.78 |
|
IMTX
Immatics NV
|
$12.5M | -$0.45 | -81.89% | -704.25% | $18.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MKKGY
Merck KGaA
|
$27.80 | $34.04 | $60.4B | 18.43x | $0.50 | 1.8% | 2.57x |
|
BAYRY
Bayer AG
|
$9.77 | $10.87 | $38.4B | -- | $0.03 | 0.31% | 0.76x |
|
BNTX
BioNTech SE
|
$96.00 | $137.68 | $23.1B | 191.55x | $0.00 | 0% | 6.53x |
|
CVAC
CureVac NV
|
$5.12 | $5.31 | $1.2B | 7.16x | $0.00 | 0% | 14.22x |
|
IFRX
InflaRx NV
|
$1.10 | $12.78 | $74.5M | -- | $0.00 | 0% | 339.88x |
|
IMTX
Immatics NV
|
$11.87 | $18.75 | $1.4B | 42.21x | $0.00 | 0% | 15.86x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MKKGY
Merck KGaA
|
29.49% | 0.204 | 25.12% | 0.76x |
|
BAYRY
Bayer AG
|
57.27% | 0.418 | 142.34% | 0.55x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MKKGY
Merck KGaA
|
$3.8B | $1.4B | 7.45% | 10.11% | 22.9% | $579.8M |
|
BAYRY
Bayer AG
|
$6.3B | $655.6M | -0.4% | -0.91% | 5.81% | $616.1M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Merck KGaA vs. Competitors
-
Which has Higher Returns MKKGY or BAYRY?
Bayer AG has a net margin of 16.89% compared to Merck KGaA's net margin of -9.93%. Merck KGaA's return on equity of 10.11% beat Bayer AG's return on equity of -0.91%.
Company Gross Margin Earnings Per Share Invested Capital MKKGYMerck KGaA60.42% $0.48 $48.3B BAYRYBayer AG55.41% -$0.29 $81.5B -
What do Analysts Say About MKKGY or BAYRY?
Merck KGaA has a consensus price target of $34.04, signalling upside risk potential of 22.45%. On the other hand Bayer AG has an analysts' consensus of $10.87 which suggests that it could grow by 11.21%. Given that Merck KGaA has higher upside potential than Bayer AG, analysts believe Merck KGaA is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings MKKGYMerck KGaA1 0 0 BAYRYBayer AG1 1 0 -
Is MKKGY or BAYRY More Risky?
Merck KGaA has a beta of 0.993, which suggesting that the stock is 0.722% less volatile than S&P 500. In comparison Bayer AG has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.835%.
-
Which is a Better Dividend Stock MKKGY or BAYRY?
Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.8%. Bayer AG offers a yield of 0.31% to investors and pays a quarterly dividend of $0.03 per share. Merck KGaA pays 24.48% of its earnings as a dividend. Bayer AG pays out 4.24% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKKGY or BAYRY?
Merck KGaA quarterly revenues are $6.2B, which are smaller than Bayer AG quarterly revenues of $11.3B. Merck KGaA's net income of $1B is higher than Bayer AG's net income of -$1.1B. Notably, Merck KGaA's price-to-earnings ratio is 18.43x while Bayer AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.57x versus 0.76x for Bayer AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKKGYMerck KGaA2.57x 18.43x $6.2B $1B BAYRYBayer AG0.76x -- $11.3B -$1.1B
-
Which has Higher Returns MKKGY or BNTX?
BioNTech SE has a net margin of 16.89% compared to Merck KGaA's net margin of -1.89%. Merck KGaA's return on equity of 10.11% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital MKKGYMerck KGaA60.42% $0.48 $48.3B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About MKKGY or BNTX?
Merck KGaA has a consensus price target of $34.04, signalling upside risk potential of 22.45%. On the other hand BioNTech SE has an analysts' consensus of $137.68 which suggests that it could grow by 43.41%. Given that BioNTech SE has higher upside potential than Merck KGaA, analysts believe BioNTech SE is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings MKKGYMerck KGaA1 0 0 BNTXBioNTech SE14 5 0 -
Is MKKGY or BNTX More Risky?
Merck KGaA has a beta of 0.993, which suggesting that the stock is 0.722% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock MKKGY or BNTX?
Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.8%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 24.48% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKKGY or BNTX?
Merck KGaA quarterly revenues are $6.2B, which are larger than BioNTech SE quarterly revenues of $1.8B. Merck KGaA's net income of $1B is higher than BioNTech SE's net income of -$33.5M. Notably, Merck KGaA's price-to-earnings ratio is 18.43x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.57x versus 6.53x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKKGYMerck KGaA2.57x 18.43x $6.2B $1B BNTXBioNTech SE6.53x 191.55x $1.8B -$33.5M
-
Which has Higher Returns MKKGY or CVAC?
CureVac NV has a net margin of 16.89% compared to Merck KGaA's net margin of -5832.47%. Merck KGaA's return on equity of 10.11% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital MKKGYMerck KGaA60.42% $0.48 $48.3B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About MKKGY or CVAC?
Merck KGaA has a consensus price target of $34.04, signalling upside risk potential of 22.45%. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 3.97%. Given that Merck KGaA has higher upside potential than CureVac NV, analysts believe Merck KGaA is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings MKKGYMerck KGaA1 0 0 CVACCureVac NV1 3 0 -
Is MKKGY or CVAC More Risky?
Merck KGaA has a beta of 0.993, which suggesting that the stock is 0.722% less volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.
-
Which is a Better Dividend Stock MKKGY or CVAC?
Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.8%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 24.48% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKKGY or CVAC?
Merck KGaA quarterly revenues are $6.2B, which are larger than CureVac NV quarterly revenues of $63.3M. Merck KGaA's net income of $1B is higher than CureVac NV's net income of $319.3M. Notably, Merck KGaA's price-to-earnings ratio is 18.43x while CureVac NV's PE ratio is 7.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.57x versus 14.22x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKKGYMerck KGaA2.57x 18.43x $6.2B $1B CVACCureVac NV14.22x 7.16x $63.3M $319.3M
-
Which has Higher Returns MKKGY or IFRX?
InflaRx NV has a net margin of 16.89% compared to Merck KGaA's net margin of -51538.49%. Merck KGaA's return on equity of 10.11% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital MKKGYMerck KGaA60.42% $0.48 $48.3B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About MKKGY or IFRX?
Merck KGaA has a consensus price target of $34.04, signalling upside risk potential of 22.45%. On the other hand InflaRx NV has an analysts' consensus of $12.78 which suggests that it could grow by 1062.2%. Given that InflaRx NV has higher upside potential than Merck KGaA, analysts believe InflaRx NV is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings MKKGYMerck KGaA1 0 0 IFRXInflaRx NV5 2 0 -
Is MKKGY or IFRX More Risky?
Merck KGaA has a beta of 0.993, which suggesting that the stock is 0.722% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock MKKGY or IFRX?
Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.8%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 24.48% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKKGY or IFRX?
Merck KGaA quarterly revenues are $6.2B, which are larger than InflaRx NV quarterly revenues of $27.8K. Merck KGaA's net income of $1B is higher than InflaRx NV's net income of -$14.3M. Notably, Merck KGaA's price-to-earnings ratio is 18.43x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.57x versus 339.88x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKKGYMerck KGaA2.57x 18.43x $6.2B $1B IFRXInflaRx NV339.88x -- $27.8K -$14.3M
-
Which has Higher Returns MKKGY or IMTX?
Immatics NV has a net margin of 16.89% compared to Merck KGaA's net margin of -974.45%. Merck KGaA's return on equity of 10.11% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital MKKGYMerck KGaA60.42% $0.48 $48.3B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About MKKGY or IMTX?
Merck KGaA has a consensus price target of $34.04, signalling upside risk potential of 22.45%. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 57.96%. Given that Immatics NV has higher upside potential than Merck KGaA, analysts believe Immatics NV is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings MKKGYMerck KGaA1 0 0 IMTXImmatics NV9 0 0 -
Is MKKGY or IMTX More Risky?
Merck KGaA has a beta of 0.993, which suggesting that the stock is 0.722% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.
-
Which is a Better Dividend Stock MKKGY or IMTX?
Merck KGaA has a quarterly dividend of $0.50 per share corresponding to a yield of 1.8%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck KGaA pays 24.48% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Merck KGaA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MKKGY or IMTX?
Merck KGaA quarterly revenues are $6.2B, which are larger than Immatics NV quarterly revenues of $6.1M. Merck KGaA's net income of $1B is higher than Immatics NV's net income of -$59.1M. Notably, Merck KGaA's price-to-earnings ratio is 18.43x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck KGaA is 2.57x versus 15.86x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MKKGYMerck KGaA2.57x 18.43x $6.2B $1B IMTXImmatics NV15.86x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
